Vasomotor Symptoms
Conditions
Keywords
HS-10384, Vasomotor symptoms, postmenopausal women
Brief summary
A randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HS-10384 in postmenopausal women suffering from vasomotor symptoms.
Detailed description
The phase 2 study is consisted with 2 doses. The aim is to detect the efficacy, safety, pharmacokinetics and pharmacodynamics characteristics of HS-10384 in participants with vasomotor symptoms.
Interventions
DRUGHS-10384 tablet Dose 1
Administered orally QD
DRUGHS-10384 tablet Dose 2
Administered orally QD
Administered orally QD
Sponsors
Hansoh BioMedical R&D Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Women between 40 and 65 years old (including extremes); 2. The body mass index at screening is between 18.5\ 30 kg/m2 (including extremes)； 3. Subjects are postmenopausal women at screening as qualified by any of the following criteria: spontaneous amenorrhea ≥ 12 months, or spontaneous amenorrhea ≥ 6 months and FSH\>40 IU/L (without other obvious pathological or physiological reasonsbefore screening), or documented surgical sterilization (such as hysterectomy, bilateral salpingectomy or bilateral oophorectomy, etc.); 4. At least 50 moderate to severe vasomotor symptoms per week (ie, 7 consecutive days), or 7 moderate to severe vasomotor symptoms per day (ie, 7 consecutive days) recorded in the daily diary during the screening period; 5. The blood pregnancy test of female subjects at baseline period is negative.
Exclusion criteria
1. Participants with disease history of unexplained uterine bleeding, endometrial hyperplasia, ovarian tumor, pituitary tumor, or other diseases evaluated by the principal investigator as not suitable for this study; 2. Have a history of migraine within 3 months before screening; 3. Uncontrolled hypertension and a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg; 4. Previous or current history of a malignant tumor, except for basal cell carcinoma; 5. Participants with clinically significant diseases (such as neuropsychiatric system, cardiovascular system, urinary system, digestive system, respiratory system, skeletal muscle system, endocrine and metabolic system, blood system, skin disease, immune system, tumor, etc.) were evaluated by the researcher as not suitable for this study; 6. Within 4 weeks or 5 half-lives (whichever is longer) before taking drug, participants have taken hormonal treatment, hormonal contraceptive or other therapy due to VMS; 7. Within 4 weeks or 5 half-lives (whichever is longer) before screening, and during the whole study period, it is expected to take any medicine and health care products, including prescription drugs, immunomodulator or Chinese herbal medicine, etc.; 8. Participants have participated in any interventional study or taken study drugs within 3 months before screening; 9. Judged by the Investigator to be unsuited to participate in the study based on findings observed during physical examination, vital sign assessment, or 12-lead electrocardiogram (ECG), et al.; 10. Active liver disease or jaundice, or values of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 x the upper limit of normal (ULN); or total bilirubin or direct bilirubin \>1.5 x ULN; 11. Creatinine \>1.5 x ULN; or estimated glomerular filtration rate (eGFR) using the CKD-EPI formula ≤59 mL/min/1.73 sqm at the screening visit;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 4; | Baseline to Week 4 |
| Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 12; | Baseline to Week 12 |
| Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 4; | Baseline to Week 4 |
| Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 12. | Baseline to Week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of treatment-emergent adverse events; | Baseline to Week 15 |
| Number of participants with clinical laboratory abnormalities; | Baseline to Week 15 |
| Number of participants with abnormalities of vital signs | Baseline to Week 15 |
| Mean change in the frequency of moderate and severe vasomotor symptoms from baseline to each study week; | Baseline to Week 15 |
| Change from baseline in ECG parameters | Baseline to Week 15 |
| Change from baseline in plasma bone density marker concentrations | Baseline to Week 15 |
| Change from baseline in Endometrial health assessment. | Baseline to Week 15 |
| Number of participants with abnormalities of physical examinations | Baseline to Week 15 |
| Mean change in the severity of moderate and severe vasomotor symptoms from baseline to each study week; | Baseline to Week 15 |
| Mean change in the hot flash score of moderate and severe vasomotor symptoms from baseline to each study week; | Baseline to Week 15 |
| Mean percent reduction of 50% and 100% of moderate and severe vasomotor symptoms from baseline to each study week. | Baseline to Week 15 |
Countries
China
Contacts
Primary ContactQi Yu, MD
Outcome results
None listed